A new paper in the Journal of Urology represents an initial attempt, based on a prospective, multi-ethnic cohort of nearly 3,000 men, to determine whether baseline PSA levels can predict, with a high level of reliability, subsequent risk for and consequential diagnosis of prostate cancer. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: baseline, Diagnosis, PSA, risk, testing | 2 Comments »
For some years, Vickers, Lilja, and their associates have been arguing that baseline PSA level is able to predict long-term risk for prostate cancer, and now a new paper in European Urology seems to provide support for this argument and a practical clinical strategy for its application. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: baseline, individualized, personalized, PSA, risk, screening, testing | 10 Comments »
According to a newly published, prospective study in the Journal of Urology, a research team at the Mayo Clinic has confirmed prior reports (based on retrospective data) that a baseline PSA in men aged between 40 and 49 years can be used to categorize men into low and higher prostate cancer risk groups. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: baseline, Diagnosis, PSA, risk, testing | 9 Comments »
Earlier, retrospective studies based on Swedish and Danish databases have suggested that men in their 40s with a single PSA level of < 1.0 ng/ml are at low risk for a diagnosis of prostate cancer for up to 30 years after that initial, baseline PSA result. … READ MORE …
Filed under: Diagnosis, Management, Risk | Tagged: baseline, Diagnosis, PSA, risk, testing | 5 Comments »
The April issue of AUA News (a magazine only available to AUA members) includes an interesting article by David Penson, MD, in which he previews a lecture he will be giving at the upcoming annual meeting of the American Urological Association (in Atlanta, later this month). … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: baseline, database, localized, outcone, regitry, standardized, trial | 6 Comments »
In September last year we provided information about a Danish study by Orsted et al. on the use of PSA levels in projecting the long-term risk of prostate cancer that had been presented at a scientific meeting in Europe. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Risk | Tagged: baseline, long-term, PSA, risk | 2 Comments »
It is well understood that a diagnosis of prostate cancer does not necessarily imply that the patient will ever have progressive disease — let alone that he will die of prostate cancer. Indeed, the number of men in America who die of prostate cancer today is believed to be significantly less than three for every 100 men diagnosed. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer | Tagged: baseline, cancer-specific, mortality, PSA, risk | 6 Comments »
Erectile dysfunction (ED) is a common medical problem with significant impact on quality of life. The existence of some degree of ED in patients with prostate cancer prior to treatment clearly has potential effects on outcomes of different treatments. Researchers at the Martini Clinic in Hamburg, Germany have now reported on baseline erectile function in prostate cancer patients prior to treatment with radical prostatectomy. … READ MORE …
Filed under: Living with Prostate Cancer, Management | Tagged: baseline, ED, erectile dysfuntion, preoperative | Leave a comment »
In a paper just published in the International Journal of Radiation Oncology Biology Physics, the authors sought to evaluate whether patients’ pretreatment serum testosterone (T) levels had any impact on survival after prostate brachytherapy. … READ MORE …
Filed under: Management, Treatment | Tagged: ADT, androgen deprivation, baseline, brachytherapy, pretreatment, serum testosterone, survival | Leave a comment »
THE "NEW" PROSTATE CANCER INFOLINK 